Shilajit Fatigue Randomized Trial: What the Evidence Says

Quick Answer

Shilajit Fatigue Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• As adults age, they often become less active, gain fat mass, and have difficulty managing blood glucose and lipid levels, thereby increasing their risk of type 2 diabetes mellitus and cardiometabolic disease. [Martinez Victoria (2025); evidence level 2]
• Metabolic syndrome (MetSyn) is defined as the presence of at least three risk factors, including abdominal obesity, hypertension, glucose intolerance, high triglycerides, and low high-density lipoprotein levels. [Martinez Victoria (2025); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For shilajit fatigue randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Martinez Victoria (2025). Effects of 12 Weeks of Chromium, Phyllanthus emblica Fruit Extract, and Shilajit Supplementation on Markers of Cardiometabolic Health, Fitness, and Weight Loss in Men and Women with Risk Factors to Metabolic Syndrome Initiating an Exercise and Diet Intervention: A Randomized Double-Blind, Placebo-Controlled Trial †. DOI: 10.3390/nu17122042. PMCID: PMC12196397. PMID: 40573153. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12196397/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.